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Abstract
Biomarker discovery aims to find small subsets of relevant variables in ‘omics data that correlate with the clinical syndromes
of interest. Despite the fact that clinical phenotypes are usually characterized by a complex set of clinical parameters,
current computational approaches assume univariate targets, e.g. diagnostic classes, against which associations are sought
for. We propose an approach based on asymmetrical sparse canonical correlation analysis (SCCA) that finds multivariate
correlations between the ‘omics measurements and the complex clinical phenotypes. We correlated plasma proteomics
data to multivariate overlapping complex clinical phenotypes from tuberculosis and malaria datasets. We discovered
relevant ‘omic biomarkers that have a high correlation to profiles of clinical measurements and are remarkably sparse,
containing 1.5–3% of all ‘omic variables. We show that using clinical view projections we obtain remarkable improvements
in diagnostic class prediction, up to 11% in tuberculosis and up to 5% in malaria. Our approach finds proteomic-biomarkers
that correlate with complex combinations of clinical-biomarkers. Using the clinical-biomarkers improves the accuracy of
diagnostic class prediction while not requiring the measurement plasma proteomic profiles of each subject. Our approach
makes it feasible to use omics’ data to build accurate diagnostic algorithms that can be deployed to community health
centres lacking the expensive ‘omics measurement capabilities.
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Introduction
The aim of biomarker discovery is to find small subsets of
measurements in ‘omics data that correlate with the clinical
syndromes or phenotypes of interest. Despite the fact that most
clinical phenotypes (e.g. diseases) are characterized by a complex
set of clinical parameters, with a variable degree of overlap,
current computational approaches do not take into consideration
the multivariate nature of the phenotypes. The challenges arise
both from the dependence of the diseases on several proteins and
from the complexity of the symptoms. To overcome this
limitation, in our framework, the data to be analysed is
represented by two views, namely a plasma proteomics profile,
and a set of clinical data composed of patient history, signs,
symptoms and clinical laboratory measurements of the individuals
with syndromes of interest. This type of problem can be described
as multivariate in both the views, and the aim is to discover a
sparse set of ‘omic variables (proteomic-biomarkers) that correlates
with a combination of clinical variables (clinical-biomarkers).
Given the typically high number of variables and small number
of patient samples in clinical ‘omic studies, dimensionality
reduction techniques such as Principal component analysis
(PCA) and Canonical Correlation Analysis (CCA) have become
popular. PCA allows one to discover a set of latent variables in the
data that explain most of the variance but they may not correlate
with the clinical syndrome of interest. In contrast, CCA performs
dimensionality reduction for two co-dependent datasets simulta-
neously so that the latent variables extracted from the two datasets
are maximally correlated. Thus, the latent variables computed
from one of the datasets can be used to predict the ones computed
from the other, which is the basic goal in biomarker discovery.
However, in both PCA and CCA, the latent variables depend on
all variables and therefore hinder clinical interpretation and
biomarker discovery and validation. To address these computa-
tional limitations sparse variants of PCA (SPCA) and CCA
(SCCA) have been independently developed [1–3]. These methods
use a L1-norm penalization to variable weights which favours
models with a small set of variables having a non-negligible weight.
Sparse approaches impose the penalisation in both views of the
data, thus generating latent variables depending on small sets of
variables [2,3]. Recently we have proposed an asymmetrical
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algorithm that imposes sparsity only in one of the data views [1] by
penalizing dual variables related to the latent variables of the other
dataset. This asymmetrical approach favours latent variables that
relate to small clusters of data points.
Here we use our asymmetrical SCCA algorithm for the
unsupervised discovery of candidate biomarkers by correlating
plasma proteomics data to multivariate clinical parameters from
two human infectious diseases namely, tuberculosis and malaria,
which present with overlapping complex clinical phenotypes in the
affected host.
Tuberculosis is the leading bacterial cause of death worldwide,
with an estimated 8.8 million new cases of active disease and 1.6
million deaths per year [4]. The global burden of TB occurs in a
background of complex disease phenotypes that range from the
presence of latent TB to respiratory and constitutional symptoms
overlapping with those of pulmonary active TB. Latent TB
infection is thought to affect one third of the world’s population
and a higher proportion of the population of TB-endemic areas
[5]. In this scenario the challenge is to distinguish symptomatic
patients with active TB from those with latent disease but whose
presenting symptomatology is attributable to some other infectious
or inflammatory process [6].
Cerebral malaria (CM) and severe malarial anemia (SMA) are
the major severe disease syndromes in African children with a high
level of mortality in the under-five age group. The current WHO
case definitions for severe malaria combine P. falciparum blood
stage parasitemia with coma, severe anemia or respiratory distress
[7], and it is well documented that there is significant overlap
across these syndromes [8].
To validate the biomarkers discovered by the SCCA approach,
we study the prediction of diagnostic classes using the biomarkers.
In particular we study a scenario were the expensive proteomics
data is only available during the training time of the models, whilst
in prediction time, clinical data and a previously learned
biomarker model is available. In our belief this is a realistic setup
considering possible real-world deployment of decision support
systems into resource-poor health care centres.
Materials and Methods
Datasets
The active TB dataset [6] consists of 412 patient data with three
datasets: serum proteome profiles measured by SELDI-ToF mass-
spectrometry [6,9] (270 variables), clinical data (19 variables) and
diagnostic classes (Active TB, Symptomatic Control, Asymptom-
atic Control).
The childhood severe malaria dataset consist of 944 patient data
with three datasets: plasma proteome profiles measured by mass-
spectrometry (774 variables), clinical data (57 variables) and
diagnostic classes (Cerebral Malaria (CM), Severe Malaria
Anaemia (SMA), Uncomplicated Malaria (UM), Disease Control
(DC) and Community Control (CC)).
Plasma was subjected to high-throughput proteomic profiling by
mass spectrometry as previously described [6,9]. The proteomics
and clinical variables were standardized by subtracting the mean
and dividing by standard deviation. Standardized proteomics and
clinical profiles were converted to unit norm vectors by dividing by
the Euclidean norm (Figure 1).
Biomarker extraction by sparse canonical correlation
analysis
Figure 1 shows a workflow of the algorithmic and experimental
framework used for biomarker extraction. We assume data in two
views, represented by da x m matrix Xa= (xa
(1),…,xa
(m)) and db x m
matrix Xb= (xb
(1),…,xb
(m)), where da and db are the dimensions of
the feature vectors in the two views. The i’th example is thus given
by a pair (xa
(i),xb
(i)).
Canonical correlation analysis (CCA) is a family of statistical
algorithms designed to situations where there are two available
views or measurements of the same phenomenon and the goal is to
find latent variables that explain both views (‘the generating
model’) [10]. The CCA algorithm aims to find projection
directions wa and wb that maximize the correlation of the projected
data, the scores sa
(i) = wa
Txa
(i) and sb
(i)=wb
Txb
(i), in the two views:
r~
wa
TCabwb
waTCaawak k wTb Cbbwb


~
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where Cab =XaXb
T is the empirical covariance matrix of the views
over the dataset. The first expression gives the correlation
computed with explicit feature weights. The second expression
gives the dual representation in terms kernel matrices Ka =Xa
T Xa
and Kb=Xb
T Xb, as well as dual variables a= (a1,…, am) and
b= (b1,…,bm) giving weights to the examples in the two views. The
corresponding projection directions are given in the dual
representation by linear combinations of examples, wa=Xaa and
wb =Xbb. When CCA is performed in dual representation, it is
commonly called Kernel Canonical Correlation Analysis (KCCA).
CCA can be applied to the data iteratively via deflation, that is,
the projection of the data to the orthogonal complement of wa and
wb, respectively, and performing the CCA analysis for the
projected data. This process results in a sequence of projections
(wa(1), wb(1)), (wa(2), wb(2)),…, (wa(r), wb(r)), where r denotes the
minimum of the numerical ranks of Xa and Xb. The resulting
projections are orthogonal to each other: wc(i)
Twc(j) = 0 if i?j,
where by c we denote either of the two views a or b. We call the
pair (wa(1), wb(1)), the leading pair of projections. By definition,
the leading pair has the maximum canonical correlation in the
Author Summary
Many infectious diseases such as tuberculosis and malaria
are challenging both for scientists trying to understand the
biochemical basis of the diseases and for medical doctors
making diagnosis. The challenges arise both from the
dependence of the diseases on sets of proteins and from
the complexity of the symptoms. Biomarkers denote small
sets of measurements that correlate with the phenotype of
interest. They have potential use both in advancing the
basic biomedical research of infectious diseases and in
facilitating predictive diagnostic tools. We propose a new
method for biomarker discovery that works by finding
canonical correlations between two sets of data, the
plasma proteomic profiles and clinical profiles of the
subjects. We show that the method is able to find
candidate proteomic biomarkers that correlate with
combinations of clinical variables, called the clinical
biomarkers. Using the clinical biomarkers improves the
accuracy of diagnostic class prediction while not requiring
the expensive plasma proteomic profiles to be measured
for each subject.
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sequence. The sequence of CCA projections is compactly
represented by the matrices Wa= (wa
(1),…, wa
(r)) and
Wb= (wb
(1),…, wb
(r)).
Sparse canonical correlation analysis differs from KCCA in that
it aims to find sparse projection directions, those that only depend
on a small number of variables. We use an asymmetric
Figure 1. Algorithm framework for biomarker extraction.
doi:10.1371/journal.pcbi.1003018.g001
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formulation of SCCA [1], where sparse projection directions are
aimed for in one view, while in the other view dual sparsity is
aimed for, meaning that each projection direction can be
expressed as a linear combination of a small number of examples.
The optimization to be solved is the following:
min
w,e
XTa w{Kbe
 2zm wk k1zc ek k1
s:t: ek k?~1,
where w denotes the projection direction in the first view, and e
denotes a vector of dual coefficients, where the coefficient ek,
k = 1…m, denotes the weight of xb
(i).
The first term of the objective aims to make the projection
scores sa =wa
TXa and sb = Kbe to match, the second term penalizes
the feature weights in the first view by 1-norm (thus imposing
sparsity), and the final term penalizes the dual variables by 1-norm
(thus imposing dual sparsity). The infinity norm in the constraint
ensures that at least one example will have non-zero dual
coefficient. This is achieved by fixing one example, indexed by
k, to have coefficient ek = 1 and allowing the rest of the coefficients
el, l?k vary. The fixed example is called the seed example. The
SCCA hyperparameters m and c control the balance between
primal and dual sparsity, in the respective views. We used m=1
and c=1 in our experimental framework.
SCCA can be applied iteratively to extract a series of projection
directions by using one of two alternative approaches. In the
deflation approach, like in CCA, deflation is used to arrive at a
sequence (w(1),e(1)), (w(2),e(2)),…,(w(r),e(r)) of r pairs of projection
directions that are orthogonal to each other. In other approach, by
selecting a set of different seed examples {s1,…,sk} one obtains a
set of (w(1),e(1)), (w(2),e(2)),…,(w(k),e(k)) projection directions, which,
in contrast to the deflation approach, are in general not
orthogonal. The rationale of not requiring orthogonality of the
components is two-fold: First, the deflation approach to generate
orthogonal components is an order of magnitude slower method,
due to the need to search for the best seed after each deflation
operation. Secondly, when using the projection directions as input
features to classification, there is no obvious benefit from the
orthogonality. The non-deflating approach produces a set of latent
variables that may have some redundancy due to near collinearity,
however, machine learning methods such as SVM are not
expected to be hampered by this. Indeed, in our tests, the SVM
accuracy on SCCA features with and without deflation was very
similar (data not shown).
Without loss of generality, we assume that the sequence is sorted
so that the pair (w(1),e(1)) has maximal canonical correlation in the
sequence. Analogously to CCA, this pair is called the leading pair.
In our experimental framework we selected seed examples by k-
means clustering of the clinical data and choosing the cluster
centers as the seeds. The value k = 3 was used for number of
clusters in the biomarker extraction experiment and the value
k = 30 in the diagnostic class prediction experiment.
Diagnostic class prediction
Figure 2 shows the workflow in diagnostic class prediction. We
assume as input clinical data and the biomarker model built by
canonical correlation analysis. In the experiments we use a model
with 60 projection directions, 30 from SCCA and 30 projection
directions from KCCA. The clinical data is projected onto the
biomarker model Wb to obtain biomarker scores zb
(i) =Wb
Txb
(i) for
each example. The Radial Basis Function (RBF) kernel
Kb(i,j)~exp { z
(i)
b {z
(j)
b

=s2
 
is used as a non-linear transformation of the biomarker scores. We
trained a Support Vector Machine (SVM) to predict diagnostic
classes by using the RBF kernel as input and the predefined
diagnostic classes as the output. As the SVM requires a binary
classification problem, we use a one-against-one scheme to train a
separate classifier for each pair of diagnostic classes. For
evaluation, 10-fold cross validation was used. The RBF kernel
parameters and the margin softness of SVM were tuned by
internal 10-fold cross-validation in each training fold.
We compared the CCA-based methodology to using raw
clinical data as the input to SVM without making use of the
biomarker model and using proteomics data processed with
principal component analysis. We used 30 first principal compo-
nents as the input to SVM.
Statistical significance testing
Statistical significance of the results was estimated using
randomization tests. In randomization, a background data
distribution consistent with the null hypothesis is generated by
simulation, where the statistical connection to be tested has been
broken, but the data distribution is otherwise kept close to the
original data. In the case of canonical correlation analysis, we want
to test if the correlation of the two views is significant, we use the
null hypothesis H0: The data Xa and Xb are not correlated’’. To
generate a sample of canonical correlation values consistent with
the null hypothesis, we generated randomized versions of the data
by permuting the rows of the data matrix Xb, and performed
canonical correlation analysis for the randomized data. This
process was repeated 500 times to generate a set of canonical
correlation values representing the distribution under the null
hypothesis. The significance level of the test is given by the fraction
of the distribution that is above the canonical correlation value
obtained on the original data. We note that the randomization
setup used here also automatically corrects for a possible multiple
testing bias.
Results
Firstly, we assessed the capabilities of SCCA for extracting
biomarkers from data that is organized in two views, ‘omics data
and clinical profile data. For this purpose, we used the leading pair
of SCCA projection directions as it encapsulates the highest
correlation between the ‘omics and clinical views. Secondly, we
assessed the utility of the extracted biomarkers in predicting
diagnostic classes. Specifically, we studied a scenario where we
assume that ‘omics data is not available in prediction phase, but
only in training phase.
Tuberculosis dataset biomarker extraction using SCCA
The leading pair of projection directions extracted from the
proteomics (view a) and clinical data (view b) by sparse canonical
correlation analysis showed a statistically significant correlation
coefficient of 0.79 (0.01% significance level). Figure 3 depicts the
correlation of the data in the directions corresponding to the
leading pair of SCCA projections. The class clusters are relatively
tight and do not overlap significantly. The leading pair of
projection directions can be seen to pick up the properties in the
data that separate active TB from symptomatic and asymptomatic
controls.
Biomarker Discovery of Complex Clinical Phenotypes
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The proteomic profile, given by the weights in the leading
projection direction wa
(1) (Figure 4) included 8 proteomic variables
with non-negligible coefficients, selected out of 271 (3%), whilst in
the clinical profile, given by the weights in wb
(1), 13 out of 18
variables had non-negligible coefficients. C-reactive protein (CRP),
has by far the largest positive weight in the clinical profile,
persistent cough (Cought7), serum amyloid protein (SAA) are other
discernible variables with positive weights, indicating that high
values for them associate more frequently with active TB cases
than the other two groups. BCG vaccination, PPD skin test, interferon-
Figure 2. Algorithm framework for diagnostic class prediction.
doi:10.1371/journal.pcbi.1003018.g002
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Figure 3. Sparse canonical correlation between proteomics and clinical profiles in the TB dataset. The x-axis gives the score in the
proteomics profile while the y-axis gives the score in the clinical profile. Data points labeled based on the three diagnostic classes Active TB (red),
Symptomatic Control (green) and Asymptomatic Control (blue). Ellipses denote the mean and covariance of the class clusters.
doi:10.1371/journal.pcbi.1003018.g003
Figure 4. TB clinical variables (a.) and plasma proteome m/z clusters (b.) with non-negligible coefficients in the SCCA model.
doi:10.1371/journal.pcbi.1003018.g004
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gamma level (IFG), and previously case of TB (PastTB) have
discernible negative weights, and thus intuitively correspond to
variables less often found among active TB cases than the other
two groups. Body mass index (BMI) and height appear with
opposite signs, consistent with the definition of BMI.
In the plasma proteomic profile the proteins at mass peaks m/z
11,475, m/z 20,884 and m/z 43,541 have the largest positive
weights (presence makes the proteomic score higher). The protein
at mass peak m/z 8,908 has the largest negative weight (absence
makes the proteomic score higher).
Malaria dataset biomarker extraction using SCCA
Figure 5 depicts the projection of the malaria data onto the
leading pair of SCCA directions. The canonical correlation
showed a statistically significant correlation coefficient of 0.75,
(0.01% significance level). The data projection clearly clustered
non-malaria community controls (CC) apart from malaria cases
UM, SMA and CM. Figure 6 shows the weights of the proteomic
and clinical variables in the leading SCCA projection directions.
Eleven proteomic variables out of 774 (1.4%) were present in the
proteomic profile wa
(1), whilst all variables were present in the
clinical profile wb
(1). The highest weights in the clinical profile,
were temperature, and O-positive blood type (BloodOPOS). In
addition, 10 other clinical variables had positive weights, roughly
indicating more abundant among the community controls than
the other classes. The highest negative weights are with presence of
malaria parasites (MP) and the presence of convulsions (HowMa-
nyConvulsions). In addition, 42 other clinical variables had negative
weights, thus intuitively less abundant among the community
controls. In the proteomic profile, the proteins at mass peaks m/z
Q10_1600_1,528, Q10_2800_8,547 and H50_1800_8,765 had the
highest positive weights and in addition three other variables had
positive weights (presence makes proteomic score higher). The
proteins at mass peaks m/z Q10_2800_4,614 and
H50_3000_20,188 had the highest negative weights (absence
makes proteomic score higher).
Diagnostic class prediction
Table 1 depicts the results of classification of the tuberculosis
data in five classes defined by the latency and the presence of
symptoms. We compared three different data: using proteomics
data processed with principal component analysis (PCA-Proteomics),
using clinical data only (Raw-Clinical) and using the clinical
projections extracted by canonical correlation analysis (K+SCCA-
Clinical). First, we observed that K+SCCA-Clinical had higher
accuracy than Raw-Clinical in distinguishing non-TB subjects from
symptomatic cases with no latent TB (85% vs. 77%) and from
symptomatic cases with latent TB (90% vs. 79%) and in
distinguishing non-TB subjects from non-symptomatic latent TB
cases (85% vs. 78% accuracy). In the other classification tasks, the
K+SCCA approach generally achieved similar level of accuracy as
using the clinical data alone. In six of the experiments PCA-
proteomics was the most accurate method, achieving 98% accuracy
or higher. In contrast, in the other four experiments the accuracy
Figure 5. Sparse canonical correlation between proteomics and clinical profiles in the childhood severe malaria dataset. The x-axis
gives the score in the proteomics profile while the y-axis gives the score in the clinical profile. Data points labeled based on the four diagnostic
classes Community Controls (black), Uncomplicated Malaria (purple), Severe Malaria Anaemia (blue) and Cerebral Malaria (red). Ellipses denote the
mean and covariance of the class clusters.
doi:10.1371/journal.pcbi.1003018.g005
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Figure 6. Malaria clinical variables (a.) and plasma proteome m/z clusters (b.) with non-negligible coefficients in the SCCA model.
doi:10.1371/journal.pcbi.1003018.g006
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of PCA-Proteomics ranges between 52%–77% and it is the least
accurate method.
Table 2 shows similar experiments for the malaria data. Here,
we considered one-against-one classification within five classes
(SMA, CM, UM, DC, and CC). We first notice that Raw-Clinical
obtained significantly higher accuracy than PCA-Proteomics alone
for all class pairs. The K+SCCA-Clinical approach achieves higher
accuracy than Raw-Clinical in two important cases: distinguishing
Severe Malaria Anaemia from Uncomplicated Malaria (90% vs. 85%)
and Severe Malaria Anaemia from Disease Control (97% vs. 92%). For
the class pairs CC vs. SMA, CC vs. UM and DC vs UM, Raw-Clinical
and the K+SCCA-Clinical achieve 99%–100% accuracy. For the
pairs CC vs. CM, CC vs. DC, and CM vs. UM, the K+SCCA-Clinical
approach is slightly inferior, and for the pairs CM vs. DC and CM
vs. SMA significantly inferior to Raw-Clinical. We also noticed that
the K+SCCA-Clinical approach was able to improve on the
proteomics data in all cases.
Discussion
In this paper, we have put forward an approach for discovering
biomarkers from plasma proteomic data by canonical correlation
to clinical data collected from the same subjects. We have also
shown an approach to predict diagnostic classes based on the
selected biomarkers.
We analysed a set of data consisting of plasma proteome and
clinical profiles. Sparse canonical correlation analysis was shown
to be effective in extracting small sets of proteomic variables, each
representing a plasma protein, that correlate with clusters of
similar clinical phenotypes in statistically significant manner (p-
value 0.01). Sparsity of the extracted biomarker models is shown
by the fact that 1.5% and 3% of the proteomics variables had non-
negligible coefficients in the malaria and TB models, respectively.
The sparsity of the ‘omic view of the SCCA model is deemed to be
crucial for interpretation by human experts, as the set of proteomic
variables to be studied remains tractable. Unlike SCCA, the
KCCA method does not impose sparsity, so the KCCA is less
amenable to human analysis.
In diagnostic class prediction, we show that via canonical
correlation analysis, it is possible to make use of proteomic data in
order to improve on the diagnostic classification, even if no
proteomics data is available at the time of prediction, only at the
time of training the model. This is a close match to a real-world
scenario of deploying a diagnostic tool to health care centres
without expensive ‘omics measurement capabilities.
In our experiments, the proposed approach appears to be
advantageous (a) when proteomics data contains a strong signal
predictive of the classification (i.e. PCA-Proteomics accuracy
higher than Raw-Clinical) that can be mediated by the K+SCCA
model, or (b) when proteomics data alone does not predict well (i.e.
PCA-Proteomics accuracy lower than Raw-Clinical) but there is a
synergistic latent signal between the proteomic and clinical profiles
that K+SCCA can pick up. In the case of TB, a strong proteomics
signal (case a) is found in six of the ten comparisons. In four of
those six cases, K+SCCA matches the performance of Raw-
Clinical, improves on Raw-Clinical on two of the cases and
marginally loses in one of the cases. Evidence of a synergistic signal
(case b) is found in four of the ten comparisons, in three of which
K+SCCA matches Raw-Clinical and in one it exceeds the
accuracy of Raw-Clinical: determining the presence of latent TB
when there are no symptoms (85% accuracy versus 77% with
clinical data alone). In malaria, first we note that the clinical data is
very strong, there are no comparisons where PCA-proteomics
exceeds the accuracy of Raw-Clinical (i.e. case a). Thus, in this
data set, the K+SCCA is required to pick out a synergistic latent
signal (case b) between the proteomic and clinical variables, in
Table 1. Diagnostic class prediction in the TB dataset.
PCA-Proteomics Raw-Clinical K+SCCA-Clinical
ACC ± s.d. ACC ± s.d. ACC ± s.d.
Active TB vs. Symptomatic Latent TB 0.7760.07 0.8760.07 0.8660.05
Active TB vs. Symptomatic No-Latent TB 0.7660.05 0.9060.04 0.9160.04
Active TB vs. No-Symptomatic Latent TB 0.9860.03 0.9260.08 0.9260.08
Active TB vs. No-Symptomatic No-Latent TB 0.9960.02 0.9460.04 0.9460.04
Symptomatic Latent-TB vs. Symptomatic No-Latent TB 0.5260.18 0.6860.16 0.7060.15
Symptomatic Latent-TB vs. No-Symptomatic Latent TB 1.0060 0.7460.14 0.7560.15
Symptomatic Latent-TB vs. No-Symptomatic No-Latent TB 1.0060 0.7960.11 0.9060.11
Symptomatic No-Latent TB vs. No-Symptomatic Latent TB 1.0060 0.9060.09 0.8760.06
Symptomatic No-Latent TB vs. No-Symptomatic No-Latent TB 0.9960.02 0.7760.13 0.8560.05
No-Symptomatic Latent TB vs. No-Symptomatic No-Latent TB 0.5960.10 0.7860.11 0.8560.10
doi:10.1371/journal.pcbi.1003018.t001
Table 2. Diagnostic class prediction in the Malaria dataset.
PCA-Proteomics Raw-Clinical K+SCCA-Clinical
ACC ± s.d. ACC ± s.d. ACC ± s.d.
CC vs. CM 0.9460.06 0.9860.02 0.9660.03
CC vs. DC 0.9160.04 0.9760.03 0.9460.04
CC vs. SMA 0.9860.04 0.9960.02 0.9960.02
CC vs. UM 0.9260.03 0.9960.01 0.9960.02
CM vs DC 0.7560.08 0.9960.02 0.8860.06
CM vs. SMA 0.6160.12 0.8860.07 0.7660.08
CM vs UM 0.7360.06 0.9360.04 0.8960.04
DC vs SMA 0.7960.09 0.9260.05 0.9760.03
DC vs UM 0.7960.06 1.0060 0.9960.02
SMA vs UM 0.7160.07 0.8560.05 0.9060.05
doi:10.1371/journal.pcbi.1003018.t002
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order to improve on the predictions from clinical data alone. This
appears to take place in two experiments: in the separation of
severe malaria anemia from both uncomplicated malaria and from
disease controls. In the comparisons involving cerebral malaria
(CM), we note that proteomics data seems to be weak in three of
the four cases, and its seems that K+SCCA is hampered by this:
Although it significantly improves over PCA-proteomics, it loses
out to Raw-Clinical.
Another observation of the experiments is that K+SCCA
benefits the prediction of the difficult class pairs more than the
easier ones: in all of the comparisons where Raw-Clinical accuracy
is below 85%, K+SCCA improves on the Raw-Clinical model.
Finally, we note that the canonical correlation analysis can also
be used in the opposite way, namely to use the clinical data to
extract more predictive biomarkers from proteomics data, and
thus enhance the understanding of the systems biology underlying
the complex phenotypes. Although this particular application was
not the main focus in the present work, in our experiments the
K+SCCA method often improved over the accuracy obtained
with proteomics data alone.
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